Prurigo nodularis is an inflammatory condition related to the skin’s nerve and immune cells, so there isn’t much you can do to prevent it. If you have PN, you can take steps to reduce flares ...

Prurigo nodularis is a chronic skin condition that causes intensely itchy bumps. These hard lumps, called nodules, often appear on areas you can easily scratch, like your arms, legs, and upper back.

A large-scale genome study uncovered IL31 as a key genetic contributor to prurigo nodularis, linking it to immune-regulatory ...

"I'm looking forward to offering this treatment option to the prurigo nodularis patients in my practice who are in desperate need of fast relief from itch, which negatively impacts their quality ...

The FDA has approved nemolizumab (Nemluvio; Galderma) as a pre-filled pen for subcutaneous injection to treat adult patients with prurigo nodularis every 4 weeks, according to a press release. 1 ...

Patients were randomized to 1.5% ruxolitinib cream applied twice daily for 12 weeks or a vehicle cream. The primary endpoint was the proportion of patients achieving at least a 4-point improvement ...

Overview Release date: December 9, 2024 Expiration date: December 9, 2025 Estimated time to complete activity: 45 minutes ...

Conclusions Nemolizumab monotherapy significantly reduced the signs and symptoms of prurigo nodularis. (Funded by Galderma; ClinicalTrials.gov number, NCT04501679; EudraCT number, 2019-004789-17.) ...

On August 13, 2024, the US Food and Drug Administration (FDA) approved nemolizumab for the treatment of adults with prurigo nodularis (PN). Approval for PN is based on data from the phase 3 ...

The Food and Drug Administration (FDA) has approved Nemluvio ® (nemolizumab-ilto) for the treatment of adults with prurigo nodularis. Interleukin (IL)-31 is a neuroimmune cytokine that is ...

Late-breaking abstract presented at EADV 2023. Kwatra SG, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389:1579-89. DOI: 10.1056/NEJMoa2301333 ...